学术探索
学术期刊
新闻热点
数据分析
智能评审

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

被引：551
作者：
Bekker, PJ
Holloway, DL
Rasmussen, AS
Murphy, R
Martin, SW
Leese, PT
Holmes, GB
Dunstan, CR
DePaoli, AM
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Quintiles, Lenexa, KS USA
[3] SFBC Int Inc, Miami, FL USA
[4] ANZAC Res Inst, Concord, NSW, Australia
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 07期
关键词：
RANKL; osteoprotegerin; osteoporosis; bone resorption; AMG; 162;
D O I：
10.1359/JBMR.040305
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis.
引用
收藏
页码：1059 / 1066
页数：8
相关论文
共 50 条
  • [1] A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
    Anderson, DM
    Maraskovsky, E
    Billingsley, WL
    Dougall, WC
    Tometsko, ME
    Roux, ER
    Teepe, MC
    DuBose, RF
    Cosman, D
    Galibert, L
    [J]. NATURE, 1997, 390 (6656) : 175 - 179
  • [2] Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone
    Atkins, GJ
    Bouralexis, S
    Haynes, DR
    Graves, SE
    Geary, SM
    Evdokiou, A
    Zannettino, ACW
    Hay, S
    Findlay, DM
    [J]. BONE, 2001, 28 (04) : 370 - 377
  • [3] The effect of a single dose of osteoprotegerin in postmenopausal women
    Bekker, PJ
    Holloway, D
    Nakanishi, A
    Arrighi, M
    Leese, PT
    Dunstan, CR
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (02) : 348 - 360
  • [4] A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
    Body, JJ
    Greipp, P
    Coleman, RE
    Facon, T
    Geurs, F
    Fermand, JP
    Harousseau, JL
    Lipton, A
    Mariette, X
    Williams, CD
    Nakanishi, A
    Holloway, D
    Martin, SW
    Dunstan, CR
    Bekker, PJ
    [J]. CANCER, 2003, 97 (03) : 887 - 892
  • [5] Osteoprotegerin and rank ligand expression in prostate cancer
    Brown, JM
    Corey, E
    Lee, ZD
    True, LD
    Yun, TJ
    Tondravi, M
    Vessella, RL
    [J]. UROLOGY, 2001, 57 (04) : 611 - 616
  • [6] The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis
    Brown, JP
    Kendler, DL
    McClung, MR
    Emkey, RD
    Adachi, JD
    Bolognese, MA
    Li, Z
    Balske, A
    Lindsay, R
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2002, 71 (02) : 103 - 111
  • [7] osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
    Bucay, N
    Sarosi, I
    Dunstan, CR
    Morony, S
    Tarpley, J
    Capparelli, C
    Scully, S
    Tan, HL
    Xu, WL
    Lacey, DL
    Boyle, WJ
    Simonet, WS
    [J]. GENES & DEVELOPMENT, 1998, 12 (09) : 1260 - 1268
  • [8] The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
    Burgess, TL
    Qian, YX
    Kaufman, S
    Ring, BD
    Van, G
    Capparelli, C
    Kelley, M
    Hsu, HL
    Boyle, WJ
    Dunstan, CR
    Hu, S
    Lacey, DL
    [J]. JOURNAL OF CELL BIOLOGY, 1999, 145 (03) : 527 - 538
  • [9] Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
    Chesnut, CH
    Bell, NH
    Clark, GS
    Drinkwater, BL
    English, SC
    Johnston, CC
    Notelovitz, M
    Rosen, C
    Cain, DF
    Flessland, KA
    Mallinak, NJS
    [J]. AMERICAN JOURNAL OF MEDICINE, 1997, 102 (01) : 29 - 37
  • [10] Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice
    Clohisy, DR
    Ramnaraine, ML
    Scully, S
    Qi, MY
    Van, G
    Tan, HL
    Lacey, DL
    [J]. JOURNAL OF ORTHOPAEDIC RESEARCH, 2000, 18 (06) : 967 - 976
12345